Navigation Links
InterMune Announces Issuance of U.S. Patent for ITMN-191
Date:2/19/2009

tment discontinuation.

In November 2008, InterMune, Roche and Pharmasset, Inc. initiated the first all-oral combination study of direct anti-virals in the absence of interferon or ribavirin, known as the INFORM-1 study. That study has completed the first dose cohort. Results of INFORM-1 are expected to be reported at a major medical conference in the second quarter of 2009.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY and a research program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on inf
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 China Cord Blood Corporation (NYSE: CO) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has filed its Annual Report ... Commission. The filed Form 20-F includes audited financial statements ... Form 20-F can be accessed by visiting the U.S. ...
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Oct. 3 NPS Pharmaceuticals,Inc. (Nasdaq: NPSP ) ... its,cash tender offer with respect to its outstanding $171.8 ... due 2008. Under,the amended terms of the tender offer, ... of the outstanding convertible notes at a,purchase price, per ...
... RICHMOND, Calif., Oct. 3 Sangamo BioSciences,Inc. (Nasdaq: ... president of research, will provide an update on the ... of the,company,s business strategy at 12:45pm (PT) on Wednesday, ... The presentation will be webcast live and may ...
... WALTHAM, Mass., Oct. 3 Thermo Fisher,Scientific ... that it has acquired Priority,Solutions International, a ... healthcare industries, following anti-trust clearance.,Priority Solutions was ... of approximately $95 million in 2006, Priority,Solutions ...
Cached Biology Technology:NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007 2NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007 3Sangamo BioSciences to Present at the 2007 BIO InvestorForum 2Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 2Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 3Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 4
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... (NIST), in collaboration with the Centers for Disease Control ... Materials (SRMs) for measurements of human exposure to environmental ... check the accuracy of tests and analytic procedures, the ... measures for emerging environmental contaminants such as perchlorate, a ...
... outside Seville, in the desert region of Andalucia, Spain, sits ... giant mirrors rippling outward. More than 600 of these mirrors, ... sun throughout the day, concentrating its rays on the central ... enough to power 6,000 homes. The sprawling site, ...
... different immunological mechanisms ensure the successful establishment and maintenance ... adverse pregnancy outcomes. In a review published in ... Institute of Life Science, College of Medicine at Swansea ... obesity on the inflammatory responses in tissues of both ...
Cached Biology News:NIST releases 2 new SRMs for monitoring human exposure to environmental toxins 2MIT research: A new sunflower-inspired pattern increases concentrated solar efficiency 2MIT research: A new sunflower-inspired pattern increases concentrated solar efficiency 3Inflammation may link obesity and adverse pregnancy outcomes 2
... Linkage: This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Mouse C2C12 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
... (PI) is a fluorescent nucleic acid dye ... As a nuclear counterstain, propidium iodide ... in color. The fluorescent red color ... fluorochromes such as FITC, Cy2 or AMCA. ...
... parameter assay for mitochondrial membrane potential ... caspases are detected by carboxyfluorescein (FAM)-labelled ... cell-permeable, non-cytotoxic and bind covalently to ... At the same time the mitochondrial ...
Biology Products: